The earnings call reflected a strong performance with record revenue growth and robust pipeline advancements. However, there were concerns regarding TPIP Phase IIb PAH data and potential market competition. The authorization of a significant share buyback indicates confidence in the company's future prospects.

Company Guidance -

Q3 2025

In the recent call, United Therapeutics Corporation provided an update on their second quarter of 2025, highlighting several key metrics and developments. The company reported a record total revenue of $799 million, marking a 12% growth over the same period in 2024, with Tyvaso DPI contributing $315 million, representing a 22% increase. This quarter marked the 12th consecutive quarter of double-digit year-over-year revenue growth. The company also emphasized the potential impact of its TETON studies in idiopathic pulmonary fibrosis and its ADVANCE OUTCOMES study in pulmonary arterial hypertension, with TETON 2 results expected in September. Financially, the company reported generating nearly $1.5 billion in annual operating cash flow and announced a $1 billion share repurchase authorization to enhance shareholder value. The call also touched upon the competitive landscape, particularly addressing concerns around TPIP's market impact, and reaffirmed confidence in their commercial portfolio and future growth prospects.

Record Earnings and Revenue Growth

United Therapeutics reported a record total revenue of $799 million, reflecting 12% growth over the second quarter of 2024. This marks the 12th consecutive quarter of double-digit year-over-year revenue growth.

Strong Performance of Tyvaso Franchise

Tyvaso DPI achieved a record total revenue of $315 million, representing 22% growth over the second quarter of 2024. The quarter also marked a record for patient shipments for Tyvaso DPI and the total Tyvaso franchise.

Robust Pipeline Developments

United Therapeutics is advancing its TETON studies in idiopathic pulmonary fibrosis and ADVANCE OUTCOMES study in pulmonary arterial hypertension. The TETON 2 study is expected to report results in September, with the potential to change the company's revenue profile.

Share Buyback Authorization

The Board of Directors authorized the repurchase of up to $1 billion in shares through March of next year, reflecting confidence in the company's near-term and long-term business prospects.

United Therapeutics (UTHR) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

UTHR Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 29, 2025	2025 (Q3)	7.40 / -	6.39	―	―	―
Jul 30, 2025	2025 (Q2)	7.29 / 6.41	5.85	9.57% (+0.56)
Apr 30, 2025	2025 (Q1)	6.70 / 6.63	6.17	7.46% (+0.46)
Feb 26, 2025	2024 (Q4)	6.40 / 6.19	4.36	41.97% (+1.83)
Oct 30, 2024	2024 (Q3)	6.52 / 6.39	5.38	18.77% (+1.01)
Jul 31, 2024	2024 (Q2)	6.50 / 5.85	5.24	11.64% (+0.61)	―
May 01, 2024	2024 (Q1)	5.74 / 6.17	4.86	26.95% (+1.31)
Feb 21, 2024	2023 (Q4)	4.19 / 4.36	2.67	63.30% (+1.69)
Nov 01, 2023	2023 (Q3)	5.10 / 5.38	4.91	9.57% (+0.47)
Aug 02, 2023	2023 (Q2)	4.57 / 5.24	2.41	117.43% (+2.83)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

UTHR Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 30, 2025	$297.56	$281.95	-5.25%
Apr 30, 2025	$300.76	$303.09	+0.77%
Feb 26, 2025	$357.50	$318.89	-10.80%
Oct 30, 2024	$352.80	$361.40	+2.44%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does United Therapeutics (UTHR) report earnings?

United Therapeutics (UTHR) is schdueled to report earning on Oct 29, 2025, Before Open (Confirmed).

What is United Therapeutics (UTHR) earnings time?

United Therapeutics (UTHR) earnings time is at Oct 29, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is UTHR EPS forecast?

UTHR EPS forecast for the fiscal quarter 2025 (Q3) is 7.4.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing